Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Grail Inc.
The Federal Trade Commission broke new ground last year in its opposition to M&A transactions and challenge of Orange Book patent listings. The biopharma community is waiting to see if deals will face similar hurdles in 2024 and whether there will be legal battles if manufacturers of drug-device combination products decline to delist their patents. Researchers advocate that the FTC extend its inquiry to device patents on GLP-1 receptor agonists, including Wegovy and Ozempic.
The Federal Trade Commission blocked or restricted several deals last year, broadening what it considers to be anticompetitive transactions. Stakeholders are looking to see if the agency will bring similar cases this year and what remedies it will seek to allow deals to go forward.
News We’re Watching: Illumina Looks At Grail Options, New AdvaMed Digital Health Division, Evolut FX Gets CE Mark
This week, Illumina responded to the European Commission’s order for it to divest Grail; StrokeDX won a global innovation competition; and the US Food and Drug Administration approved expanded labeling for Boston Scientific’s WaveWriter Alpha to include painful diabetic peripheral neuropathy.
Harbinger Health has raised a total of $190m since its founding in 2021. Its CEO Stephen Hahn told Medtech Insight in March that the company plans to develop a blood-based cancer test that is affordable, accessible and also more accurate than currently available tests.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- GRAILBio Cirina Ltd
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.